Výsledky vyhledávání - "Lucio, Catalano"

Akademický článek

Strategy for the treatment and follow-up of sinonasal solitary extramedullary plasmacytoma: a case series

Autor: Elena Cantone, Antonella Miriam Di Lullo, Luana Marano, Elia Guadagno, Gelsomina Mansueto, Pasquale Capriglione, Lucio Catalano, Maurizio Iengo

Publikováno v: Journal of Medical Case Reports, Vol 11, Iss 1, Pp 1-6 (2017)

Abstract Background Extramedullary plasmacytoma is a rare neoplasm characterized by monoclonal proliferation of plasma cells outside bone marrow. It accounts for 4% of all non-epithelial sinonasal tumors. According to the literature, radiotherapy is

Externí odkaz: https://doaj.org/article/c6badc5e1c0549c79c6a73f9291d1253

Zobrazit plný text záznamu

Chemo or Chemo-Free Regimens in Heavily Pretreated Multiple Myeloma? Role of Bendamustine-Bortezomib-Dexamethasone (BVD) in NOVEL Agents' Era

Autor: Claudio Cerchione, Lucio Catalano, Davide Nappi, Anna Emanuele Pareto, Gerardo Musuraca, Sonia Ronconi, Michela Ceccolini, Giovanni Martinelli, Fabrizio Pane

Publikováno v: Blood. 140:12585-12586

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::087c8659dd2eede7b62776155c2e3396
https://doi.org/10.1182/blood-2022-170484

Zobrazit plný text záznamu

MM-498 Addition of Carfilzomib as a Third Agent in Lenalidomide-Refractory Multiple Myeloma: Switching From Doublet to Triplet

Autor: Claudio Cerchione, Lucio Catalano, Davide Nappi, Sonia Ronconi, Delia Cangini, Michela Ceccolini, Gerardo Musuraca, Matteo Marchesini, Fabrizio Pane, Giovanni Martinelli

Publikováno v: Clinical Lymphoma Myeloma and Leukemia. 22:S426-S427

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::034f63ee20170d776fff39a5f984b33b
https://doi.org/10.1016/s2152-2650(22)01630-5

Zobrazit plný text záznamu

Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials

Publikováno v: Hematological oncologyREFERENCES. 40(5)

In combination with lenalidomide and dexamethasone (KRd), Carfilzomib has been approved for the treatment of relapsed and refractory multiple myeloma (RRMM) on ASPIRE trial. Efficacy and safety of the triplet are still the object of investigation by

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::73c564266e71807b21ea3941128c9dd3
https://pubmed.ncbi.nlm.nih.gov/35638723

Zobrazit plný text záznamu

Akademický článek

Retreatment with Bendamustine-Bortezomib-Dexamethasone in a Patient with Relapsed/Refractory Multiple Myeloma

Autor: Claudio Cerchione, Davide Nappi, Maria Di Perna, Irene Zacheo, Anna Emanuele Pareto, Marco Picardi, Lucio Catalano, Fabrizio Pane

Publikováno v: Case Reports in Hematology, Vol 2016 (2016)

The clinical management of relapsed/refractory multiple myeloma and the correct choice of the most suitable therapy in heavily pretreated and fragile patients are tough clinical issues for clinicians. In advanced phases of disease, the choice of avai

Externí odkaz: https://doaj.org/article/ab51cd43838f4f29842bdcf98d34712e

Zobrazit plný text záznamu

Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study

Autor: Paola Tacchetti, Lucia Pantani, Francesca Patriarca, Maria Teresa Petrucci, Elena Zamagni, Luca Dozza, Monica Galli, Francesco Di Raimondo, Claudia Crippa, Mario Boccadoro, Simona Barbato, Patrizia Tosi, Franco Narni, Vittorio Montefusco, Nicoletta Testoni, Antonio Spadano, Carolina Terragna, Norbert Pescosta, Giulia Marzocchi, Claudia Cellini, Piero Galieni, Sonia Ronconi, Marco Gobbi, Lucio Catalano, Antonio Lazzaro, Giovanni De Sabbata, Clotilde Cangialosi, Fabrizio Ciambelli, Pellegrino Musto, Francesca Elice, Michele Cavo, Renato Fanin, Roberto Foa', Alessandro Rambaldi, Giuseppe Rossi, Pietro Leoni, Paolo Corradini, Giuseppe Torelli, Giuseppe Fioritoni, Sergio Cortelazzo, Giorgio Lambertenghi Deliliers, Giorgio La Nasa, Alfonso Zaccaria, Paolo De Fabritiis, Nicola Cascavilla, Alberto Bosi, Gianpietro Semenzato, Luigi Gugliotta, Filippo Gherlinzoni, Emanuele Angelucci, Massimo Fabrizio Martelli, Maria Concetta Petti, Giuseppe Leone, Angelo Michele Carella, Fabio Ciceri, Armando Santoro, Felicetto Ferrara, Francesco Nobile, Alfonso Maria D'Arco, Alessandro Levis, Luciano Guardigni, Andrea Gallamini, Pier Paolo Fattori, Sergio Morandi, Dino Amadori, Bruno Rotoli, Salvatore Mirto, Giorgio Paladini, Ruggero Mozzana, Graziella Pinotti, Francesco Rodeghiero, Nicola Cantore, Vincenzo Pavone, Enrico Maria Pogliani, Anna Marina Liberati, Ignazio Majolino, Sergio Amadori, Francesco Lauria, Massimo Aglietta, Giovanni Quarta, Sergio Storti, Fortunato Morabito, Silvana Franca Capalbo, Alessandro Massimo Gianni, Vincenzo Mettivier, Vittorio Rizzoli, Carlo Bernasconi, Giuseppe Visani, Michele Pizzuti, Giacinto La Verde, Giuseppe Avvisati, Maurizio Longinotti, Eugenio Gallo, Franco Dammacco, Domenico Russo, Andrea Bacigalupo, Caterina Musolino

Publikováno v: The Lancet Haematology. 7:e861-e873

Background: The phase 3 GIMEMA-MMY-3006 trial, which compared bortezomib, thalidomide, and dexamethasone (VTD) combination therapy with thalidomide and dexamethasone (TD) as induction therapy before and consolidation therapy after double autologous h

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d247cf6931cb796a2568e2552250ca02
https://doi.org/10.1016/s2352-3026(20)30323-9

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání